Abstract
Non-melanoma skin cancers (NMSC) comprised of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the most common human cancers [14,24,25]. The annual incidence of NMSC is rapidly increasing, with an average increase between 3% and 6% per year in most populations, and has been reported to be almost 1000 per 100000 people in Australia [1, 14, 24]. An estimated 2750000 new cases of NMSC occurred worldwide in 1985. It is also estimated that there were 1200000 cases of BCC in the United States in 1995 [1, 15]. BCC is by far the most common skin malignancy throughout the world, accounting for about 75% of NMSC [15, 24] Given that the incidence of NMSC continues to increase yearly, the dermatologist will diagnose and treat an increasing number of patients with skin cancer. The majority of BCC begin as small lesions typically less than 1 cm in diameter that can be successfully treated in a variety of ways [15,26]. Treatment goals focus on complete tumor removal and minimization of cosmetic and functional defects. Effective methods of treatment include excisional surgery, curettage and electrodesiccation, cryosurgery, radiotherapy, and Mohs’ micrographic surgery [15]. However, many BCC may present considerable therapeutic difficulties because of the location of the tumor, its size, and the age of the patient. Large and recurrent tumors, in particular, usually require extensive resection with rotation of tissue or free or composite grafts. Recently, results from several clinical trials have shown that intralesional interferon (IFN) is an effective treatment modality for BCC [4, 8, 9, 11, 22].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Armstrong BK, Kricker A (1995) Skin cancer. Dermatol Clin 13:583–594.
Baron S, Tyring SK, Fleishmann WR (1991) The interferons: mechanism of action and clinical application. JAMA 266:1375–1383.
Boneschi V, Brambilla L, Chiappino G, Mozzanica N, Finzi AF (1991) Intralesional alpha 2b recombinant interferon for basal cell carcinoma. Int J Dermatol 30:220–224.
Bottomley WW, Keczkes K (1991) Treatment of basal cell carcinomas with intralesional recombinant interferon-alfa-2b. J Dermatol Treat 2:15–16.
Buechner SA (1991) Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. J Am Acad Dermatol 24:731–734.
Buechner SA, Lautenschlager S, Schiller P, Itin P, Bigliardi P, Izakovic J, Yilmaz B, Miiller D, Courvoisier S (1995) Treatment of basal cell carcinomas with intralesional interferon alfa-2b. Dermatology 191:173–174.
Chimenti S, Cotellessa C, Peris K, Di Cristofaro S, Fargnoli MC, Torlone G (1995a) Use of recombinant interferon alpha-2a in the treatment of squamous cell carcinoma. J Dermatol Treat 6:163–166.
Chimenti S, Peris K, Di Cristofaro S, Fargnoli MC, Torlone G (1995b) Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma. Dermatology 190:214–217.
Cornell RC, Greenway HT, Tucker SB, Edwards L, Ashworth S, Vance JC, Tanner DJ, Taylor EL, Smiles KA, Peets EA (1990) Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 23:694–700.
DiLorenzo PA, Goodman N, Lansville F, Markel W (1994) Regional and intralesional treatment of invasive basal cell carcinoma with interferon alfa-n2b. J Am Acad Dermatol 31:109–111.
Edwards L, Tucker SB, Perednia D, Smiles KA, Taylor EL, Tanner DJ, Peets EA (1990a) The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinoma. Arch Dermatol 126:1029–1032.
Edwards L, Whiting D, Rogers D, Luck K, Smiles KA (1990b) The effect of intralesional interferon gamma on basal cell carcinomas. J Am Acad Dermatol 22:496–500.
Edwards L, Berman B, Rapini RP, Whiting DA, Tyring S, Greenway HT, Eyre SP, Tanner DJ, Taylor EL, Peets E, Smiles KA (1992) Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy. Arch Dermatol 128:1486–1489.
Gloster HM, Brodland DG (1996) The epidemiology of skin cancer. Dermatol Surg 22:217–226.
Goldberg LH (1996) Basal cell carcinoma. Lancet 347:663–667.
Greenway HT, Cornell RC, Tanner DJ, Peets E, Bordin GM, Nagi C (1986) Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol 15:437–443.
Gresser I (1990) Biolologic effects of interferons. J Invest Dermatol 95:668 71S.
Grob JJ, Collet AM, Munoz MH, Bonerandi JJ (1988) Treatment of large basal cell carcinomas with intralesional interferon alpha-2a. Lancet 1:878–879.
Hahn S, Gehri R, Erb P (1995) Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol Rev 146:57–79.
Healsmith MR Berth-Jones J, Fletcher A, Graham-Brown RAC (1991) Treatment of basal cell carcinoma with intralesinal interferon alpha-2b. J R Soc Med 84:524–526
Hunt MJ, Halliday GM, Weedon D, Cooke BE, Barnetson RS (1994) Regression in basal cell carcinoma: an immunohistochemical analysis. Br f Dermatol 130:1–8.
Ikic D, Padovan I, Pipic N, Knezevic M, Djakovic N, Rode B, Kosutic I, Beleza M (1991) Basal cell carcinomatreated with interferon, Int J Dermatol 30:734–737
Knop J (1990) Immunologic effects of interferon. J Invest Dermatol 95:72s–74s.
Marks R (1995a) The epidemiology of non-melanoma skm cancer: who whv and what can we do about it. J Dermatol 22:853–857.
Marks R (1995b) An overview of skin cancers. Incidence and causation. C ancer 75:607–612.
Motley RJ (1995) The treatment of basal cell carcinoma. J Dermatol Treat 6:121–125.
Mozzanica N, Cattaneo A, Boneschi V, Brambilla I, Melotti E, Pinzi AF (1990) Immunohisto- logical evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha-2-interferon. Arch Dermatol Res 282:311–317.
Nagata S, Golstein P (1995) The Fas death factor. Science 267:1449–1456.
Oishi M, Maeda K, Sugi va ma S (1994) Distribution of apoptosis-mediating Fas antigen in human skin and effects of anti Fas monoclonal antibody on human epidermal keratinocyte and squamous cell carcinoma cell lines. Arch Dermatol Res 286:396–407.
Rodriguez-Villanueva J, McDonnell TJ (1995) Induction of apoptotic cell death in non-melanoma skin cancer by interferon a Int J Cancer 61:110–114.
Stadler R, Ruszczak Z (1993) interferons. New additions and indications for use. Dermatol Clin 11:187–199.
Stalder T, Hahn S, Erb P (1994) has antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol 152:1127–1133.
Stenquist B, Wennberg AM, Gisslen H, Larko O (1992) Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery. J Am Acad Dermatol 27:65–69.
Tank B, Habets JMW, Naafs B, Damsma O, Stolz E, van loost T (1989) Intraiesional treatment of basal cell carcinoma with low-dose recombinant interferon gamma. J Am Acad Dermatol 21:734–735.
Thestrup-Pedersen K, Jacobsen IE, Frentz G (1990)Intralesional Interferon a 2b treatment of basal cell carcinoma. Acta Derm Venereol (Stockh) 70:512–514
Tong Y, Tucker SB (1993) Normal human skin lvmphoi vtic and Langerhans cell responses to intradermal interferon a-2b injections. Am J Med Sci W6:23–27.
Wickramasinghe L, Hindson TC, Wacks H (1989) Treatment of neoplastic skin lesions with intralesional interferon. I Am Acad Dermatol 20:71–74.
Williams GT(1994) Apoptosis in the immune system. J Pathol 173:1–4
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Buechner, S.A. (1997). Non-melanoma Skin Cancer. In: Burg, G., Dummer, R.G. (eds) Strategies for Immunointerventions in Dermatology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60752-3_30
Download citation
DOI: https://doi.org/10.1007/978-3-642-60752-3_30
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64539-6
Online ISBN: 978-3-642-60752-3
eBook Packages: Springer Book Archive